PROMIS NEUROSCIENCES INC. Accounts Payable
PROMIS NEUROSCIENCES INC. (PMN) had Accounts Payable of $1.79 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2026-08-13
- 2026-06-30: Accounts Payable, Current $1.79M.
- 2026-03-31: Accounts Payable, Current $1.72M.
- 2025-12-31: Accounts Payable, Current $2.54M.
- 2025-09-30: Accounts Payable, Current $4.21M.
| Period end | Accounts Payable, Current |
|---|---|
| 2026-06-30 | $1.79M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $1.72M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $2.54M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $4.21M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $2.78M 10-Q · filed 2025-08-13 |
| 2025-03-31 | $1.20M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $1.74M 10-K · filed 2026-03-25 |
| 2024-09-30 | $1.58M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $2.02M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $1.40M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $7.84M 10-K · filed 2025-03-31 |
| 2023-09-30 | $8.41M 10-Q · filed 2023-11-14 |
| 2023-06-30 | $7.96M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $6.99M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $2.98M 10-K · filed 2024-04-01 |
| 2022-09-30 | $1.79M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $888.01K 10-Q · filed 2022-08-12 |
| 2021-12-31 | $408.98K 10-K · filed 2023-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |